Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.78
(0.0%)
EUR 0.78
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.14 Million EUR | -69.51% |
| 2022 | -987.94 Thousand EUR | -181.44% |
| 2021 | -355.67 Thousand EUR | -386.92% |
| 2020 | 275.07 Thousand EUR | 116.12% |
| 2019 | -1.04 Million EUR | 41.59% |
| 2018 | -1.6 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.22 Million EUR | 0.0% |
| 2024 Q1 | -1.22 Million EUR | 12.28% |
| 2023 FY | - EUR | -69.51% |
| 2023 Q3 | -1.94 Million EUR | -140.26% |
| 2023 Q4 | -1.93 Million EUR | 0.48% |
| 2023 Q2 | -808.89 Thousand EUR | -93.17% |
| 2023 Q1 | -418.74 Thousand EUR | 41.45% |
| 2022 Q2 | -665.64 Thousand EUR | -163.07% |
| 2022 FY | - EUR | -181.44% |
| 2022 Q3 | -391.3 Thousand EUR | 41.21% |
| 2022 Q1 | -253.02 Thousand EUR | 44.79% |
| 2022 Q4 | -715.19 Thousand EUR | -82.77% |
| 2021 FY | - EUR | -386.92% |
| 2021 Q1 | -13.47 Thousand EUR | -105.78% |
| 2021 Q2 | -32.36 Thousand EUR | -140.11% |
| 2021 Q3 | -238.64 Thousand EUR | -637.46% |
| 2021 Q4 | -458.27 Thousand EUR | -92.03% |
| 2020 Q2 | -221.09 Thousand EUR | -2046.71% |
| 2020 FY | - EUR | 116.12% |
| 2020 Q3 | 147.84 Thousand EUR | 166.87% |
| 2020 Q1 | -10.29 Thousand EUR | 0.0% |
| 2020 Q4 | 233.25 Thousand EUR | 57.76% |
| 2019 FY | - EUR | 41.59% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | 1.59 Million EUR | 234.618% |
| Philogen S.p.A. | -2.04 Million EUR | -4.659% |